Financial Performance - The company's revenue for Q3 2024 was ¥272,937,625.99, representing a 22.55% increase year-over-year[2] - The net profit attributable to shareholders was ¥9,734,618.01, a decrease of 131.04% compared to the same period last year[2] - The basic earnings per share for the quarter was ¥0.0837, down 131.13% year-over-year[2] - Total operating revenue for the current period is ¥735,466,949.07, a decrease of 2.0% compared to ¥750,999,036.22 in the previous period[14] - Net profit for the current period is a loss of ¥34,034,829.25, compared to a profit of ¥74,120,088.16 in the previous period[15] - The company reported a basic and diluted earnings per share of -0.3017, compared to 0.6492 in the previous period[15] - The company recorded a total comprehensive loss of ¥34,034,829.25 for the current period, compared to a comprehensive income of ¥74,120,088.16 in the previous period[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,303,464,207.37, an increase of 8.71% from the end of the previous year[2] - The total assets of Jiangsu Hualv Biotechnology Group reached approximately CNY 2.30 billion as of September 30, 2024, an increase from CNY 2.12 billion at the beginning of the period[10] - Current assets decreased to CNY 561.75 million from CNY 627.85 million, primarily due to a reduction in cash and cash equivalents, which fell from CNY 409.95 million to CNY 336.85 million[10] - Non-current assets rose significantly to CNY 1.74 billion from CNY 1.49 billion, driven by an increase in fixed assets from CNY 1.23 billion to CNY 1.20 billion[11] - Total liabilities increased to CNY 801.04 million from CNY 551.03 million, reflecting a rise in both current and non-current liabilities[11] - The total equity attributable to shareholders decreased by 4.56% to ¥1,477,138,727.84 compared to the end of the previous year[2] - The company's equity attributable to shareholders decreased to CNY 1.48 billion from CNY 1.55 billion, a decline of approximately 4.5%[13] Cash Flow - The cash flow from operating activities for the quarter was ¥71,453,388.10, a decrease of 48.82% compared to the same period last year[6] - Operating cash flow for the current period is ¥680,807,623.75, an increase of 10.6% from ¥615,603,832.95 in the previous period[16] - Cash inflow from operating activities totaled ¥752,261,011.85, slightly down from ¥755,204,046.02 in the previous period[16] - Investment cash outflow amounted to ¥216,139,993.27, compared to ¥239,110,231.10 in the previous period[16] - The net cash flow from investing activities was -216,083,665.59 CNY, compared to -74,837,878.37 CNY in the previous period[17] - The total cash inflow from financing activities was 236,345,877.87 CNY, up from 79,042,254.25 CNY year-over-year[17] - The net cash flow from financing activities was 71,531,541.32 CNY, a significant improvement from -9,352,246.42 CNY in the previous period[17] - The cash and cash equivalents at the end of the period decreased to 336,854,042.32 CNY from 487,060,903.57 CNY[17] - Cash paid for debt repayment was 104,292,038.04 CNY, an increase from 55,842,308.61 CNY year-over-year[17] Investments and Projects - The company reported a significant increase in construction in progress, rising by 120.36% to ¥206,164,118.02 due to new projects[6] - The company recorded a net cash outflow from investment activities of ¥216,083,665.59, an increase of 188.74% year-over-year, attributed to new project investments[6] - The company is focusing on expanding its market presence and developing new products, although specific figures were not disclosed in the report[12] - Future outlook remains optimistic with ongoing investments in technology and market expansion strategies planned for the upcoming quarters[12] Expenses - Total operating costs increased to ¥772,482,385.40, up 14.4% from ¥675,263,870.84 in the previous period[14] - Research and development expenses decreased to ¥11,772,434.56, down 10.3% from ¥13,177,331.95 in the previous period[14] - Sales expenses increased to ¥8,024,933.44, up 13.3% from ¥7,083,830.72 in the previous period[14] - Financial expenses for the quarter were ¥2,055,286.82, a change of -193.94% compared to the previous year, primarily due to reduced financial investments and increased interest expenses[6] Government Support - The company received government subsidies amounting to ¥190,488.04 during the quarter, contributing positively to the financial results[4] Audit Status - The company did not undergo an audit for the third quarter report[17]
华绿生物(300970) - 2024 Q3 - 季度财报